Literature DB >> 25600754

Early-life risperidone administration alters maternal-offspring interactions and juvenile play fighting.

Matthew A Gannon1, Clifford J Brown1, Rachel M Stevens1, Molly S Griffith1, Cecile A Marczinski1, Mark E Bardgett2.   

Abstract

Risperidone is an antipsychotic drug that is approved for use in childhood psychiatric disorders such as autism. One concern regarding the use of this drug in pediatric populations is that it may interfere with social interactions that serve to nurture brain development. This study used rats to assess the impact of risperidone administration on maternal-offspring interactions and juvenile play fighting between cage mates. Mixed-sex litters received daily subcutaneous injections of vehicle or 1.0 or 3.0mg/kg of risperidone between postnatal days (PNDs) 14-42. Rats were weaned and housed three per cage on PND 21. In observations made between PNDs 14-17, risperidone significantly suppressed several aspects of maternal-offspring interactions at 1-hour post-injection. At 23 h post-injection, pups administered risperidone had lower activity scores and made fewer non-nursing contacts with their moms. In observations of play-fighting behavior made once a week between PNDs 22-42, risperidone profoundly decreased many forms of social interaction at 1h post-injection. At 23h post-injection, rats administered risperidone made more non-social contacts with their cage mates, but engaged in less social grooming. Risperidone administration to rats at ages analogous to early childhood through adolescence in humans produces a pattern of abnormal social interactions across the day that could impact how such interactions influence brain development.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antipsychotic; Autism; Development; Dopamine; Forebrain; Social behavior

Mesh:

Substances:

Year:  2015        PMID: 25600754      PMCID: PMC4357390          DOI: 10.1016/j.pbb.2015.01.007

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  44 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Who are the new users of antipsychotic medications?

Authors:  Marisa Elena Domino; Marvin S Swartz
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

3.  Juvenile peer play experience and the development of the orbitofrontal and medial prefrontal cortices.

Authors:  Heather C Bell; Sergio M Pellis; Bryan Kolb
Journal:  Behav Brain Res       Date:  2009-09-26       Impact factor: 3.332

4.  Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.

Authors:  S Kapur; R B Zipursky; G Remington
Journal:  Am J Psychiatry       Date:  1999-02       Impact factor: 18.112

5.  Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study.

Authors:  Justine M Kent; Stuart Kushner; Xiaoping Ning; Keith Karcher; Seth Ness; Michael Aman; Jaskaran Singh; David Hough
Journal:  J Autism Dev Disord       Date:  2013-08

6.  Adult rats treated with risperidone during development are hyperactive.

Authors:  Mark E Bardgett; Julie M Franks-Henry; Kristin R Colemire; Kathleen R Juneau; Rachel M Stevens; Cecile A Marczinski; Molly S Griffith
Journal:  Exp Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.157

7.  Social interactions in adolescent and adult Sprague-Dawley rats: impact of social deprivation and test context familiarity.

Authors:  Elena I Varlinskaya; Linda P Spear
Journal:  Behav Brain Res       Date:  2007-12-08       Impact factor: 3.332

8.  Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.

Authors:  Christina Kurre Olsen; Lise Tøttrup Brennum; Mads Kreilgaard
Journal:  Eur J Pharmacol       Date:  2008-02-12       Impact factor: 4.432

Review 9.  Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.

Authors:  Benedetto Vitiello; Christoph Correll; Barbara van Zwieten-Boot; Alessandro Zuddas; Mara Parellada; Celso Arango
Journal:  Eur Neuropsychopharmacol       Date:  2009-05-24       Impact factor: 4.600

10.  Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats.

Authors:  Jenny L Wiley
Journal:  Eur J Pharmacol       Date:  2007-09-26       Impact factor: 4.432

View more
  2 in total

1.  Early-life risperidone enhances locomotor responses to amphetamine during adulthood.

Authors:  Bobbie Lee Stubbeman; Clifford J Brown; Justin R Yates; Mark E Bardgett
Journal:  Eur J Pharmacol       Date:  2017-07-14       Impact factor: 4.432

2.  Delayed yet persistent effects of daily risperidone on activity in developing rats.

Authors:  Rachel M Stevens; Matthew A Gannon; Molly S Griffith; Mark E Bardgett
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.